Technical Analysis for KRYS - Krystal Biotech, Inc.

Grade Last Price % Change Price Change
grade D 45.02 1.28% 0.57
KRYS closed up 1.28 percent on Friday, September 13, 2019, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It ran into resistance at its 50 day moving average.

Earnings due: Sep 27

*** please verify all earnings dates ***
2 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Flat Up
See historical KRYS trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Bearish Engulfing Bearish 1.28%
Fell Below 50 DMA Bearish 1.28%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.28%
Upper Bollinger Band Walk Strength 1.28%
Outside Day Range Expansion 1.28%
Upper Bollinger Band Touch Strength 1.28%

Older signals for KRYS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
KRYS Chart by TradingView
Basic chart:
Profile
Krystal Biotech, Inc. gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. The Company has developed a Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases. The Company’s products include KB103 and KB104.The Compnay's KB103 is in preclinical development to treat dystrophic epidermolysis bullosa, or DEB, a rare and severe genetic disease. The Compnay's KB104 is to treat Netherton Syndrome, a severe form of ichthyosis, which is a family of genetic skin disorders associated with thickened scaly skin and characterized by chronic skin inflammation, itchiness, dehydration and stunted growth.
Medicine Rare Diseases Gene Therapy Medical Genetics Genetic Genealogy Genodermatoses Herpes Simplex Virus Epidermolysis Bullosa Itchiness Netherton Syndrome
Is KRYS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Sep 4 Krystal Biotech initiates early-stage study of gene therapy for rare skin disorder
Sep 4 Krystal Biotech Announces Initiation of Phase 1/2 Study of KB105 in Transglutaminase-1 (“TGM1”) Deficient Autosomal Recessive Congenital Ichthyosis (“ARCI”)
Aug 27 Krystal Biotech Announces Attendance at Citi’s 14th Annual Biotech Conference
Aug 14 Have Insiders Been Buying Krystal Biotech, Inc. (NASDAQ:KRYS) Shares?
Aug 5 Krystal Biotech EPS misses by $0.05
Aug 5 Krystal Biotech Reports Second Quarter 2019 Financial and Operating Results
Jul 1 Krystal Biotech added to the Russell 2000 Index
Jul 1 Krystal Biotech, Inc. Added to the Russell 2000 Index
Jul 1 3 Small-Cap Biotech Stocks That Soared Last Week
Jun 27 Hedge Funds Have Never Been This Bullish On Krystal Biotech, Inc. (KRYS)
See more KRYS news...
Indicators
Indicator Value
52 Week High 51.6699
52 Week Low 14.3
Average Volume 157,246
200-Day Moving Average 32.0317
50-Day Moving Average 45.0464
20-Day Moving Average 43.81
10-Day Moving Average 44.162
Average True Range 3.2626
ADX 14.07
+DI 21.3911
-DI 17.3186
Chandelier Exit (Long, 3 ATRs ) 38.3672
Chandelier Exit (Short, 3 ATRs ) 49.1578
Upper Bollinger Band 47.7501
Lower Bollinger Band 39.8699
Percent B (%b) 0.65
BandWidth 17.987218
MACD Line 0.33
MACD Signal Line 0.0969
MACD Histogram 0.2332
Fundamentals Value
Market Cap 434.15 Million
Num Shares 9.64 Million
EPS -0.63
Price-to-Earnings (P/E) Ratio -71.46
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 48.80
Resistance 3 (R3) 48.87 47.68 48.17
Resistance 2 (R2) 47.68 46.72 47.64 47.96
Resistance 1 (R1) 46.35 46.12 47.01 46.28 47.75
Pivot Point 45.16 45.16 45.49 45.13 45.16
Support 1 (S1) 43.83 44.20 44.50 43.76 42.29
Support 2 (S2) 42.64 43.61 42.61 42.08
Support 3 (S3) 41.32 42.64 41.87
Support 4 (S4) 41.24